NO20051451D0 - Pyrimidinderivater og deres anvendelse som CB2 modulatorer - Google Patents

Pyrimidinderivater og deres anvendelse som CB2 modulatorer

Info

Publication number: NO20051451D0
Authority: NO; Norway
Prior art keywords: modulators; pyrimidine derivatives; pyrimidine; derivatives
Prior art date: 2002-08-21

Application number

NO20051451A

Other languages

English (en)

Norwegian (no)

Other versions

NO20051451L (no

Inventor

Derek Anthony Rawlings

Andrew John Eatherton

Gerard Martin Paul Giblin

Richard Howard Green

William Leonard Mitchell

Alan Naylor

Brian Peter Slingsby

Andrew Richard Wittington

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-21

Filing date

2005-03-18

Publication date

2005-03-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31948030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20051451(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-08-21 Priority claimed from GB0219501A external-priority patent/GB0219501D0/en

2003-04-24 Priority claimed from GB0309326A external-priority patent/GB0309326D0/en

2005-03-18 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2005-03-18 Publication of NO20051451D0 publication Critical patent/NO20051451D0/no

2005-03-18 Publication of NO20051451L publication Critical patent/NO20051451L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

NO20051451A 2002-08-21 2005-03-18 Pyrimidinderivater og deres anvendelse som CB2 modulatorer NO20051451L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0219501A GB0219501D0 (en)	2002-08-21	2002-08-21	Compounds
GB0309326A GB0309326D0 (en)	2003-04-24	2003-04-24	Compounds
PCT/EP2003/009217 WO2004018433A1 (en)	2002-08-21	2003-08-19	Pyrimidine derivatives and their use as cb2 modulators

Publications (2)

Publication Number	Publication Date
NO20051451D0 true NO20051451D0 (no)	2005-03-18
NO20051451L NO20051451L (no)	2005-03-18

Family

ID=31948030

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20051451A NO20051451L (no)	2002-08-21	2005-03-18	Pyrimidinderivater og deres anvendelse som CB2 modulatorer

Country Status (34)

Country	Link
US (2)	US7635701B2 (is)
EP (2)	EP1878725B1 (is)
JP (1)	JP4583174B2 (is)
KR (1)	KR20050058367A (is)
CN (1)	CN100351239C (is)
AP (1)	AP2005003219A0 (is)
AR (1)	AR041016A1 (is)
AT (2)	ATE489369T1 (is)
AU (1)	AU2003264076B2 (is)
BR (1)	BR0313676A (is)
CA (1)	CA2495880C (is)
CY (1)	CY1107871T1 (is)
DE (2)	DE60335151D1 (is)
DK (1)	DK1539712T3 (is)
EA (2)	EA012703B1 (is)
EC (1)	ECSP055613A (is)
ES (1)	ES2295682T3 (is)
IL (2)	IL166552A0 (is)
IS (1)	IS7749A (is)
MA (1)	MA27428A1 (is)
MX (1)	MXPA05001960A (is)
MY (1)	MY137053A (is)
NO (1)	NO20051451L (is)
NZ (1)	NZ537886A (is)
OA (1)	OA12910A (is)
PE (1)	PE20040898A1 (is)
PL (1)	PL376047A1 (is)
PT (1)	PT1539712E (is)
SI (1)	SI1539712T1 (is)
TW (1)	TW200410946A (is)
UA (1)	UA83194C2 (is)
UY (1)	UY27939A1 (is)
WO (1)	WO2004018433A1 (is)
ZA (1)	ZA200500913B (is)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UY27939A1 (es)	2002-08-21	2004-03-31	Glaxo Group Ltd	Compuestos
WO2004029204A2 (en)	2002-09-27	2004-04-08	Merck & Co., Inc.	Substituted pyrimidines
AR043633A1 (es) *	2003-03-20	2005-08-03	Schering Corp	Ligandos de receptores de canabinoides
US20040259887A1 (en) *	2003-06-18	2004-12-23	Pfizer Inc	Cannabinoid receptor ligands and uses thereof
GB0402356D0 (en) *	2004-02-03	2004-03-10	Glaxo Group Ltd	Novel compounds
GB0402355D0 (en) *	2004-02-03	2004-03-10	Glaxo Group Ltd	Novel compounds
AU2005231507B2 (en)	2004-04-08	2012-03-01	Targegen, Inc.	Benzotriazine inhibitors of kinases
EP1799656A4 (en)	2004-08-25	2009-09-02	Targegen Inc	HETEROCYCLIC COMPOUNDS AND METHODS OF USE
GB0517188D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
US8133900B2 (en)	2005-11-01	2012-03-13	Targegen, Inc.	Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en)	2005-11-01	2013-12-10	Targegen, Inc.	Bi-aryl meta-pyrimidine inhibitors of kinases
HUE028987T2 (en)	2005-11-01	2017-01-30	Targegen Inc	Bi-aryl meta-pyrimidine inhibitors of kinases
WO2007070760A2 (en)	2005-12-15	2007-06-21	Boehringer Ingelheim International Gmbh	Compounds which modulate the cb2 receptor
JP2009536613A (ja) *	2006-04-07	2009-10-15	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｂ２受容体を調節する化合物
US7935715B2 (en)	2006-07-28	2011-05-03	Boehringer Ingelheim International Gmbh	Compounds which modulate the CB2 receptor
WO2008032764A1 (en) *	2006-09-13	2008-03-20	Kyowa Hakko Kirin Co., Ltd.	Fused heterocyclic derivative
MX2009002888A (es)	2006-09-25	2009-03-31	Boehringer Ingelheim Int	Compuestos que modulan el receptor cb2.
ES2344128T3 (es) *	2006-10-04	2010-08-18	F. Hoffmann-La Roche Ag	Derivados de pirazina-2-carboxamida como moduladores de receptores cb2.
WO2008048914A1 (en) *	2006-10-17	2008-04-24	Boehringer Ingelheim International Gmbh	Polycyclic compounds which modulate the cb2 receptor
CA2695613A1 (en)	2006-12-19	2008-06-26	Pharmos Corporation	Sulfonamide derivatives with therapeutic indications
GB0705803D0 (en) *	2007-03-28	2007-05-02	Glaxo Group Ltd	Novel compounds
JP2011503013A (ja) *	2007-11-06	2011-01-27	エモリー・ユニバーシテイ	安全なｎｍｄａ受容体拮抗薬を同定する方法
CA2704684A1 (en)	2007-11-07	2009-05-14	Boehringer Ingelheim International Gmbh	Compounds which modulate the cb2 receptor
CA2730037A1 (en)	2008-07-10	2010-01-14	Boehringer Ingelheim International Gmbh	Sulfone compounds which modulate the cb2 receptor
PE20110397A1 (es)	2008-09-25	2011-07-01	Boehringer Ingelheim Int	Compuestos que modulan selectivamente el receptor cb2
TW201031650A (en) *	2008-12-02	2010-09-01	Organon Nv	1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione
TW201031649A (en)	2008-12-02	2010-09-01	Organon Nv	1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives
WO2010113834A1 (ja)	2009-03-30	2010-10-07	アステラス製薬株式会社	ピリミジン化合物
US8299103B2 (en)	2009-06-15	2012-10-30	Boehringer Ingelheim International Gmbh	Compounds which selectively modulate the CB2 receptor
JP5756800B2 (ja)	2009-06-16	2015-07-29	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体
EP2480544A1 (en)	2009-09-22	2012-08-01	Boehringer Ingelheim International GmbH	Compounds which selectively modulate the cb2 receptor
EP2523936A1 (en)	2010-01-15	2012-11-21	Boehringer Ingelheim International GmbH	Compounds which modulate the cb2 receptor
US8329735B2 (en)	2010-03-05	2012-12-11	Boehringer Ingelheim International Gmbh	Tetrazole compounds which selectively modulate the CB2 receptor
WO2012012307A1 (en)	2010-07-22	2012-01-26	Boehringer Ingelheim International Gmbh	Sulfonyl compounds which modulate the cb2 rece
PL2599774T3 (pl) *	2010-07-29	2017-01-31	Astellas Pharma Inc.	Skondensowane związki pirydynowe, jako ligandy receptorów kannabinoidowych cb2
WO2012060847A1 (en)	2010-11-07	2012-05-10	Targegen, Inc.	Compositions and methods for treating myelofibrosis
WO2014143661A1 (en) *	2013-03-15	2014-09-18	Waterfi, Llc	Method for water-proofing elecronic components
EP2803668A1 (en)	2013-05-17	2014-11-19	Boehringer Ingelheim International Gmbh	Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
EP3060566B1 (en) *	2013-10-23	2018-09-05	Academia Sinica	Compounds for use in prevention and treatment of neurodegenerative diseases and pain
JP6983868B2 (ja)	2016-04-22	2021-12-17	レセプター・ホールディングス・インコーポレイテッド	即効性の植物由来医薬化合物及び栄養補給剤
EA201892396A1 (ru)	2016-12-02	2019-04-30	Ресептор Лайф Сайенсиз, Инк.	Быстродействующие растительные лекарственные соединения и биологически активные добавки
CA3120001A1 (en)	2018-11-19	2020-05-28	Receptor Holdings, Inc.	N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5518A (en)		1848-04-18		Geaijst-drieb
US4826689A (en)	1984-05-21	1989-05-02	University Of Rochester	Method for making uniformly sized particles from water-insoluble organic compounds
FR2634376B1 (fr)	1988-07-21	1992-04-17	Farmalyoc	Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
IT1227626B (it)	1988-11-28	1991-04-23	Vectorpharma Int	Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
US5112820A (en) *	1990-03-05	1992-05-12	Sterling Drug Inc.	Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
IT1243390B (it)	1990-11-22	1994-06-10	Vectorpharma Int	Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5552160A (en)	1991-01-25	1996-09-03	Nanosystems L.L.C.	Surface modified NSAID nanoparticles
US5145684A (en)	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
HUT63941A (en) *	1992-05-15	1993-11-29	Hoechst Ag	Process for producing 4-alkyl-substituted pyrimidine-5-carboxanilide derivatives, and fungicidal compositions comprising same
DK0644755T3 (da)	1992-06-10	1997-09-22	Nanosystems Llc	Overflademodificerede NSAID-nanopartikler
FR2692575B1 (fr)	1992-06-23	1995-06-30	Sanofi Elf	Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5346702A (en)	1992-12-04	1994-09-13	Sterling Winthrop Inc.	Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en)	1992-12-04	1994-03-29	Sterling Winthrop Inc.	Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en)	1992-12-09	1994-04-12	Sterling Winthrop Inc.	Method to reduce particle size growth during lyophilization
US5340564A (en)	1992-12-10	1994-08-23	Sterling Winthrop Inc.	Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en)	1992-12-11	1994-08-09	Sterling Winthrop Inc.	Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en)	1992-12-15	1995-07-04	Eastman Kodak Company	Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en)	1992-12-16	1994-10-04	Sterling Winthrop Inc.	Use of purified surface modifiers to prevent particle aggregation during sterilization
US5474995A (en)	1993-06-24	1995-12-12	Merck Frosst Canada, Inc.	Phenyl heterocycles as cox-2 inhibitors
EP0723533A1 (en) *	1993-10-12	1996-07-31	The Du Pont Merck Pharmaceutical Company	1n-alkyl-n-arylpyrimidinamines and derivatives thereof
US5466823A (en)	1993-11-30	1995-11-14	G.D. Searle & Co.	Substituted pyrazolyl benzenesulfonamides
US5587143A (en)	1994-06-28	1996-12-24	Nanosystems L.L.C.	Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5585108A (en)	1994-12-30	1996-12-17	Nanosystems L.L.C.	Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5560932A (en)	1995-01-10	1996-10-01	Nano Systems L.L.C.	Microprecipitation of nanoparticulate pharmaceutical agents
US5662883A (en)	1995-01-10	1997-09-02	Nanosystems L.L.C.	Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en)	1995-01-10	1997-09-09	Nanosystems L.L.C.	Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560931A (en)	1995-02-14	1996-10-01	Nawosystems L.L.C.	Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5571536A (en)	1995-02-06	1996-11-05	Nano Systems L.L.C.	Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en)	1995-02-08	1996-04-02	Eastman Kodak Company	Isolation of ultra small particles
US5622938A (en)	1995-02-09	1997-04-22	Nano Systems L.L.C.	Sugar base surfactant for nanocrystals
US5518738A (en)	1995-02-09	1996-05-21	Nanosystem L.L.C.	Nanoparticulate nsaid compositions
US5534270A (en)	1995-02-09	1996-07-09	Nanosystems Llc	Method of preparing stable drug nanoparticles
US5591456A (en)	1995-02-10	1997-01-07	Nanosystems L.L.C.	Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en)	1995-02-13	1996-11-12	Nano Systems L.L.C.	Redispersible nanoparticulate film matrices with protective overcoats
US5633272A (en)	1995-02-13	1997-05-27	Talley; John J.	Substituted isoxazoles for the treatment of inflammation
ES2183935T3 (es)	1995-02-13	2003-04-01	Searle & Co	Isoxazoles sustituidos para el tratamiento de la inflamacion.
US5510118A (en)	1995-02-14	1996-04-23	Nanosystems Llc	Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en)	1995-02-15	1996-12-03	Nano Systems L.L.C.	Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5565188A (en)	1995-02-24	1996-10-15	Nanosystems L.L.C.	Polyalkylene block copolymers as surface modifiers for nanoparticles
US5718919A (en)	1995-02-24	1998-02-17	Nanosystems L.L.C.	Nanoparticles containing the R(-)enantiomer of ibuprofen
US5747001A (en)	1995-02-24	1998-05-05	Nanosystems, L.L.C.	Aerosols containing beclomethazone nanoparticle dispersions
US5811428A (en)	1995-12-18	1998-09-22	Signal Pharmaceuticals, Inc.	Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
AU726522B2 (en) *	1995-09-01	2000-11-09	Signal Pharmaceuticals, Inc.	Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
UA57002C2 (uk)	1995-10-13	2003-06-16	Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі.	Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
ATE386506T1 (de)	1995-10-17	2008-03-15	Jagotec Ag	Verabreichung unlöslicher arzneistoffe
FR2742148B1 (fr) *	1995-12-08	1999-10-22	Sanofi Sa	Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
DK0892791T3 (da)	1996-04-12	2003-06-23	Searle & Co	N-[[4-(5-methyl-3-phenylisoxazol-4-yl]-phenyl]-sulfonylpropylamid og dets natriumsalt som prodrugs for COX-2-inhibitorer
CN1152863C (zh)	1996-07-18	2004-06-09	麦克弗罗斯特(加拿大)公司	作为环氧合酶-2选择性抑制剂的取代的吡啶类化合物及其组合物
WO1998035666A1 (en)	1997-02-13	1998-08-20	Nanosystems Llc	Formulations of nanoparticle naproxen tablets
CO4960662A1 (es)	1997-08-28	2000-09-25	Novartis Ag	Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
DE69816651T2 (de)	1997-09-05	2004-04-01	Glaxo Group Ltd., Greenford	2,3-diaryl-pyrazolo[1,5-b]pyridazin derivate, deren herstellung und deren verwendung als cyclooxygenase 2 (cox-2) inhibitoren
US6022884A (en) *	1997-11-07	2000-02-08	Amgen Inc.	Substituted pyridine compounds and methods of use
EP1089714B1 (en)	1998-06-19	2003-03-05	Skyepharma Canada Inc.	Processes to generate particles of water-insoluble compounds of up to 2000 nm in size
WO2000018374A1 (en)	1998-10-01	2000-04-06	Elan Pharma International, Ltd.	Controlled release nanoparticulate compositions
DE69919887T2 (de)	1998-11-03	2005-09-15	Glaxo Group Ltd., Greenford	Pyrazolopyridin derivative als selektive cox-2 inhibitoren
US6180136B1 (en)	1998-11-10	2001-01-30	Idexx Laboratories, Inc.	Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
WO2000030615A1 (en)	1998-11-20	2000-06-02	Rtp Pharma Inc.	Method of preparing stable suspensions of insoluble microparticles
US6025683A (en)	1998-12-23	2000-02-15	Stryker Corporation	Motor control circuit for regulating a D.C. motor
GB9828511D0 (en)	1998-12-24	1999-02-17	Zeneca Ltd	Chemical compounds
AU2661400A (en)	1999-02-27	2000-09-21	Glaxo Group Limited	Pyrazolopyridines
GB9927844D0 (en) *	1999-11-26	2000-01-26	Glaxo Group Ltd	Chemical compounds
EP1175214B1 (en)	1999-12-08	2004-11-24	Pharmacia Corporation	Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
GB0003224D0 (en)	2000-02-11	2000-04-05	Glaxo Group Ltd	Chemical compounds
KR100786927B1 (ko)	2000-06-28	2007-12-17	스미스클라인비이참피이엘시이	습식 분쇄방법
GB0016877D0 (en)	2000-07-11	2000-08-30	Astrazeneca Ab	Chemical compounds
AU2001293784B2 (en)	2000-08-31	2007-08-30	F. Hoffmann-La Roche Ag	7-OXO pyridopyrimidines as inhibitors of a cellular proliferation
GB0021494D0 (en)	2000-09-01	2000-10-18	Glaxo Group Ltd	Chemical comkpounds
ATE478670T1 (de)	2001-01-29	2010-09-15	Univ Connecticut	Rezeptor-selektive cannabimimetische aminoalkylindole
US7507767B2 (en)	2001-02-08	2009-03-24	Schering Corporation	Cannabinoid receptor ligands
CZ20032233A3 (cs)	2001-02-20	2004-12-15	Bristol-Myers Squibb Company	Derivát 2,4-disubstituovaného pyrimidin-5-karboxamidu jako modulátor draslíkového kanálku KCNQ
FR2839718B1 (fr)	2002-05-17	2004-06-25	Sanofi Synthelabo	Derives d'indole, leur procede de preparation et les compositions pharmaceutiques en contenant
US7217732B2 (en)	2002-06-19	2007-05-15	Schering Corporation	Cannabinoid receptor agonists
AU2003244098A1 (en)	2002-06-28	2004-01-19	Yamanouchi Pharmaceutical Co., Ltd.	Diaminopyrimidinecarboxa mide derivative
UY27939A1 (es) *	2002-08-21	2004-03-31	Glaxo Group Ltd	Compuestos
JP2005539036A (ja)	2002-08-21	2005-12-22	グラクソ　グループ　リミテッド	ピリミジン化合物
WO2004029204A2 (en)	2002-09-27	2004-04-08	Merck & Co., Inc.	Substituted pyrimidines
GB0222493D0 (en)	2002-09-27	2002-11-06	Glaxo Group Ltd	Compounds
GB0222495D0 (en)	2002-09-27	2002-11-06	Glaxo Group Ltd	Compounds
AR043633A1 (es)	2003-03-20	2005-08-03	Schering Corp	Ligandos de receptores de canabinoides

2003
- 2003-08-14 UY UY27939A patent/UY27939A1/es not_active Application Discontinuation
- 2003-08-19 DK DK03792388T patent/DK1539712T3/da active
- 2003-08-19 SI SI200331088T patent/SI1539712T1/sl unknown
- 2003-08-19 MY MYPI20033143A patent/MY137053A/en unknown
- 2003-08-19 DE DE60335151T patent/DE60335151D1/de not_active Expired - Lifetime
- 2003-08-19 JP JP2004530220A patent/JP4583174B2/ja not_active Expired - Fee Related
- 2003-08-19 AP AP2005003219A patent/AP2005003219A0/xx unknown
- 2003-08-19 EP EP07119063A patent/EP1878725B1/en not_active Expired - Lifetime
- 2003-08-19 DE DE60317348T patent/DE60317348T2/de not_active Expired - Lifetime
- 2003-08-19 EA EA200700934A patent/EA012703B1/ru not_active IP Right Cessation
- 2003-08-19 PT PT03792388T patent/PT1539712E/pt unknown
- 2003-08-19 AR ARP030102997A patent/AR041016A1/es unknown
- 2003-08-19 UA UAA200501583A patent/UA83194C2/ru unknown
- 2003-08-19 US US10/524,470 patent/US7635701B2/en not_active Expired - Fee Related
- 2003-08-19 CA CA2495880A patent/CA2495880C/en not_active Expired - Fee Related
- 2003-08-19 MX MXPA05001960A patent/MXPA05001960A/es active IP Right Grant
- 2003-08-19 PL PL03376047A patent/PL376047A1/xx not_active Application Discontinuation
- 2003-08-19 ES ES03792388T patent/ES2295682T3/es not_active Expired - Lifetime
- 2003-08-19 BR BR0313676-0A patent/BR0313676A/pt not_active IP Right Cessation
- 2003-08-19 OA OA1200500052A patent/OA12910A/en unknown
- 2003-08-19 AT AT07119063T patent/ATE489369T1/de not_active IP Right Cessation
- 2003-08-19 AT AT03792388T patent/ATE377591T1/de active
- 2003-08-19 AU AU2003264076A patent/AU2003264076B2/en not_active Ceased
- 2003-08-19 TW TW092122692A patent/TW200410946A/zh unknown
- 2003-08-19 EA EA200500392A patent/EA010130B1/ru not_active IP Right Cessation
- 2003-08-19 WO PCT/EP2003/009217 patent/WO2004018433A1/en not_active Ceased
- 2003-08-19 EP EP03792388A patent/EP1539712B1/en not_active Expired - Lifetime
- 2003-08-19 KR KR1020057002813A patent/KR20050058367A/ko not_active Ceased
- 2003-08-19 PE PE2003000839A patent/PE20040898A1/es not_active Application Discontinuation
- 2003-08-19 CN CNB038241293A patent/CN100351239C/zh not_active Expired - Fee Related
- 2003-08-19 NZ NZ537886A patent/NZ537886A/en unknown
2005
- 2005-01-27 IL IL16655205A patent/IL166552A0/xx unknown
- 2005-02-01 ZA ZA200500913A patent/ZA200500913B/xx unknown
- 2005-02-18 EC EC2005005613A patent/ECSP055613A/es unknown
- 2005-03-07 MA MA28132A patent/MA27428A1/fr unknown
- 2005-03-17 IS IS7749A patent/IS7749A/is unknown
- 2005-03-18 NO NO20051451A patent/NO20051451L/no not_active Application Discontinuation
2007
- 2007-08-27 IL IL185549A patent/IL185549A0/en unknown
2008
- 2008-01-31 CY CY20081100115T patent/CY1107871T1/el unknown
2009
- 2009-10-21 US US12/582,861 patent/US20100041654A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE60317348D1 (de)	2007-12-20
CY1107871T1 (el)	2013-06-19
JP4583174B2 (ja)	2010-11-17
ES2295682T3 (es)	2008-04-16
CA2495880A1 (en)	2004-03-04
CN1688552A (zh)	2005-10-26
EP1878725B1 (en)	2010-11-24
MY137053A (en)	2008-12-31
JP2006501228A (ja)	2006-01-12
TW200410946A (en)	2004-07-01
EA200500392A1 (ru)	2005-08-25
AU2003264076B2 (en)	2007-09-20
EP1878725A3 (en)	2008-01-30
DE60335151D1 (de)	2011-01-05
ATE377591T1 (de)	2007-11-15
ZA200500913B (en)	2006-07-26
NZ537886A (en)	2007-05-31
NO20051451L (no)	2005-03-18
WO2004018433A1 (en)	2004-03-04
CN100351239C (zh)	2007-11-28
UY27939A1 (es)	2004-03-31
IS7749A (is)	2005-03-17
CA2495880C (en)	2010-04-27
US20100041654A1 (en)	2010-02-18
HK1079193A1 (en)	2006-03-31
EA012703B1 (ru)	2009-12-30
MA27428A1 (fr)	2005-07-01
ATE489369T1 (de)	2010-12-15
EA200700934A1 (ru)	2007-08-31
UA83194C2 (ru)	2008-06-25
AU2003264076A1 (en)	2004-03-11
EP1539712A1 (en)	2005-06-15
DE60317348T2 (de)	2008-08-28
US7635701B2 (en)	2009-12-22
EA010130B1 (ru)	2008-06-30
PE20040898A1 (es)	2005-01-07
PL376047A1 (en)	2005-12-12
DK1539712T3 (da)	2008-03-17
AR041016A1 (es)	2005-04-27
OA12910A (en)	2006-10-13
AP2005003219A0 (en)	2005-03-31
EP1539712B1 (en)	2007-11-07
MXPA05001960A (es)	2005-04-28
PT1539712E (pt)	2008-02-08
IL166552A0 (en)	2006-01-15
US20060293354A1 (en)	2006-12-28
KR20050058367A (ko)	2005-06-16
IL185549A0 (en)	2008-01-06
BR0313676A (pt)	2005-06-21
ECSP055613A (es)	2005-04-18
EP1878725A2 (en)	2008-01-16
SI1539712T1 (sl)	2008-04-30

Publication	Publication Date	Title
DK1539712T3 (da)	2008-03-17	Pyrimidinderivater og deres anvendelse som CB2-modulatorer
DK1478629T3 (da)	2007-01-29	N-aryl-2-oxazolidinon-5-carboxamider og deres derivater og deres anvendelse som antibakterielle midler
DK1480955T3 (da)	2007-10-29	O-cyclopropyl-carboxanilider og deres anvendelse som fungicider
NO20055135D0 (no)	2005-11-02	Fenylguinoliner og deres anvendelse som ostrogenreseptormodulatorer
DK1594867T3 (da)	2008-07-21	Phenylacetamider og deres anvendelse som glucokinasemodulatorer
DK1558615T3 (da)	2007-12-03	Purin-forbindelser og deres anvendelse som cannabinoid receptor ligander
NO20044137L (no)	2004-11-25	Aminoindazolderivater, deres fremstilling og anvendelse samt mellomprodukter
DK1480962T3 (da)	2011-12-05	5-Phenylthiazol-derivater og deres anvendelse som P1-3-kinaseinhibitorer
NO20031952L (no)	2003-07-22	3-aroylinderivater og deres anvendelse som CB2 reseptoragonister
DK1723128T3 (da)	2013-02-18	Heteroarylurinstoffer og deres anvendelse som glucokinaseaktivatorer
DK1498413T3 (da)	2011-12-05	4-aminopicolinater og deres anvendelse som herbicider
DK1487805T3 (da)	2012-10-15	Pyrimidinderivater
ATE438628T1 (de)	2009-08-15	Pyridazinderivate
ATE472536T1 (de)	2010-07-15	Pyridin- und pyrimidin-derivate
NO20043536L (no)	2004-08-24	Fluorsubstituerte sykloalkanoindoler og deres anvendelse som prostaglandin D2-reseptorantagonister
EP1546115A4 (en)	2010-08-04	Substituted pyrimidines
DK1419152T3 (da)	2011-10-24	HIV-hæmmende pyrimidin-derivater
NO20034324L (no)	2003-09-26	Bipiperidinylderivater og deres anvendelse som kjemokin reseptorinhibitor
NO20042719L (no)	2004-06-28	Substituerte 2-amino-cykloalkankarboksamider og deres anvendelse som protease-inhibitorer
DK1636228T3 (da)	2009-02-23	Nye pyridopyraziner og deres anvendelse som kinasemodulatorer
NO20025150D0 (no)	2002-10-25	2-acylindolderivater og deres anvendelse som antitumormidler
NO20050665L (no)	2005-04-18	Pyrrolidonderivater som MAOE inhibitoere
DK1581518T3 (da)	2011-06-06	Substituerede 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazin-derivater og deres anvendelse som neurokinin antagonister
NO20044665L (no)	2004-12-03	Renzoksazin-derivater som 5-HT6-modulatorer og anvendelser derav
NO20043580L (no)	2004-09-21	Quinazolinonderivater og deres bruk som CB agonister

Legal Events

Date	Code	Title	Description
2011-04-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application